Effect of Osteroporosis Therapy & Bone Marker Change in Peri Menopousal Women
폐경기 여성에서의 골다공증 치료 약제간의 효과 및 골 대사 지표 변화
전, 유진; 이, 태영; 공, 미희; 주, 남석; 박, 샛별
Journal of Korean Society of Osteoporosis, 5(1):27-36, 2007
Journal of Korean Society of Osteoporosis; 대한골다공증학회지
Objectives: There is on the increase of risk of osteoporosis to pre and post menopausal women and there are many medication to treat osteoporosis. But the studies to comparison of effectiveness of osteoporosis treatment and prevention are mostly from western people. So, the study to comparison of effectiveness of medication to treat and prevent of osteoporosis is needed to Korean pre and post menopausal women.
Methods: A total of 131 Pre and post women who visit health examination center in January 2000 - june 2004 who aged from 40 to 78 devided into four group. bisphosphonate(alendronateR, risedronateR, once in a weekly), raloxifene(evistaR 60mg/d), hormone replacement therapy group(conjugated equine estrogen(CEE) 0.625mg/d. medroxyprogesterone acetate(MPA) 2.5mg/d) and no medication group. Number of each group was 30, 29, 42, 30. we have test BMI(kg/m2), blood pressure, blood sugar, cholesterol, liver function test by venous sampling. Lumbar spine(L2-L4) and femoral head BMD were measured by dual x-ray absorptiometry(DXA) at baseline and at 12-month intervals. Lumbar spine(L2-L4) and femoral head BMD, bone marker(NTX, osteocalcin), serum cholesterol level were measured and repeat same test 1 year after. Serum cholesterol included total cholesterol, triglyceride(TG), low density lipoprotein(LDL), high density lipoprotein(HDL).
Results: All change in BMD, BMD T-score, bone marker, cholesterol level were different between each of treat group. The increase of lumbar spine(L2-L4) BMD in bisphosphonate group 6.93% and HRT group 5.14% was greater than raloxifene group 2.03%(P-value 0.000). The increase of lumbar spine(L2-L4) BMD T-score in HRT group 40.91% was greater than raloxifene group 11.46%(P-value 0.004). The increase of femoral head BMD in bisphosphonate group(6.87%) was greater than raloxifenegroup(2.75%)(P-value 0.010). there was no differences in femoral head BMD T-score among the groups. There was no differences among the groups in bone marker(NTX, osteocalcin). In comparison of cholesterol change rate, the increase of HDL in raloxifene group(15.05%) was greater than bisphosphonate(-0.35%) and HRT(-0.69%) group(P-value <0.05). There was no differences among the groups in total cholesterol, TG, LDL.
Conclusion: Bisphosphonate and HRT is significantly greater effect of increasing lumbar vertebral(L2∼L4) and femoral head BMD. Raloxifeneis not significantly effect of increasing lumbar vertebral(L2-L4) and femoral head BMD than bisphosphonate, HRT group. But raloxifene have greater effect of increasing HDL. There was no differences among the groups in bone marker(NTX, osteocalcin).
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :2,913,921
Total Download :1,177,365
Today View :1,010
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.